This study was the answer to a recent quiz solved by ‘julescat’ (#msg-44002107, #msg-44000662). It’s the only HCV study (as far as I know) where two oral agents—of which neither has completed even a phase-2a study—are being combined in a regimen that does not include interferon or ribavirin.
New quiz question: What other consequential feature of this trial is a first in the HCV arena?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.